Top

Open Access 05-11-2024 | Thyroid Cancer | Research

SATB2 is an Emergent Biomarker of Anaplastic Thyroid Carcinoma: A Series with Comprehensive Biomarker and Molecular Studies

Authors: Dingani Nkosi, William E. Crowe, Brian J. Altman, Zoltán N. Oltvai, Ellen J. Giampoli, Moises J. Velez

Abstract

Anaplastic thyroid carcinoma (ATC) is a rare and aggressive thyroid malignancy typically comprised of undifferentiated tumor cells with various histologic morphologies, which makes the diagnosis challenging. These tumors commonly show loss of thyroglobulin and TTF1 with preservation of cytokeratin (67%) and Paired Box Gene 8 (PAX8) (55%) expression. Identification of a sensitive immunohistochemical stain to aid in the diagnosis of ATC would be beneficial. Immunohistochemistry (IHC) against special AT-rich sequence-binding protein 2 (SATB2) protein is a sensitive and specific marker expressed in colorectal adenocarcinoma and bone or soft tissue tumors with osteoblastic differentiation. However, SATB2 is also expressed in other sarcomatous/undifferentiated neoplasms lacking osteoblastic differentiation. Using quantitative reverse transcription PCR (RT-qPCR) we showed that there is variable expression of SATB2 mRNA expression in ATCs. To evaluate the role of SATB2 protein expression in ATC, we performed PAX8, SATB2, pancytokeratin (AE1/AE3 & CAM5.2), claudin-4 and TTF1 immunostaining on 23 cases. ATCs showed retained expression of PAX8 in 65% (15/23); SATB2 was detected in 74% (17/23); pancytokeratin was expressed in 65% (15/23); claudin-4 was expressed in 35% (8/23) and TTF1 showed expression in 13% (3/23) of cases. Furthermore, 83% (5/6) of ATCs which lacked SATB2 expression, retained PAX8 expression, while 88% (7/8) of the tumors without PAX8 expression were positive for SATB2. Differentiated follicular cell-derived thyroid cancers (n = 30), differentiated high grade thyroid carcinoma (n = 3), and poorly differentiated thyroid carcinoma (n = 8) were negative for SATB2 immunoreactivity. Next-generation selected cases detected the commonly identified oncogenic variants including those in BRAF, RAS, TP53, and TERT promoter. Overall, we hereby demonstrate that SATB2 IHC may be used to support the diagnosis of ATC.

Available only for authorised users

Gilliland FD,Hunt WC,Morris DM,Key CR. (1997). Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer, 79(3), 564-573. https://doi.org/10.1002/(sici)1097-0142(19970201)79:3<564::aid-cncr20>3.0.co;2-0CrossRefPubMed

Abe I,Lam AK. (2021). Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging. Histol Histopathol, 36(3), 239-248. https://doi.org/10.14670/HH-18-277CrossRefPubMed

Ragazzi M,Ciarrocchi A,Sancisi V,Gandolfi G,Bisagni A,Piana S. (2014). Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol, 2014, 790834. https://doi.org/10.1155/2014/790834CrossRefPubMedPubMedCentral

WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours: Lyon, France; International Agency for Research on Cancer: 2022, 10, https://tumourclassification.iarc.who.int.

Bible KC,Kebebew E,Brierley J,Brito JP,Cabanillas ME,Clark TJ, Jr.,Di Cristofano A,Foote R,Giordano T,Kasperbauer J, et al. (2021). 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 31(3), 337-386. https://doi.org/10.1089/thy.2020.0944CrossRefPubMedPubMedCentral

Filetti S,Durante C,Hartl D,Leboulleux S,Locati LD,Newbold K,Papotti MG,Berruti A,clinicalguidelines@esmo.org EGCEa. (2019). Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol, 30(12), 1856-1883. https://doi.org/10.1093/annonc/mdz400CrossRefPubMed

Xu B,Fuchs T,Dogan S,Landa I,Katabi N,Fagin JA,Tuttle RM,Sherman E,Gill AJ,Ghossein R. (2020). Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid, 30(10), 1505-1517. https://doi.org/10.1089/thy.2020.0086CrossRefPubMedPubMedCentral

Landa I,Ibrahimpasic T,Boucai L,Sinha R,Knauf JA,Shah RH,Dogan S,Ricarte-Filho JC,Krishnamoorthy GP,Xu B, et al. (2016). Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest, 126(3), 1052-1066. https://doi.org/10.1172/JCI85271CrossRefPubMedPubMedCentral

Jannin A,Escande A,Al Ghuzlan A,Blanchard P,Hartl D,Chevalier B,Deschamps F,Lamartina L,Lacroix L,Dupuy C, et al. (2022). Anaplastic Thyroid Carcinoma: An Update. Cancers (Basel), 14(4), 1061. https://doi.org/10.3390/cancers14041061CrossRefPubMed

10.

Sheehan-Rooney K,Palinkasova B,Eberhart JK,Dixon MJ. (2010). A cross-species analysis of Satb2 expression suggests deep conservation across vertebrate lineages. Dev Dyn, 239(12), 3481-3491. https://doi.org/10.1002/dvdy.22483CrossRefPubMedPubMedCentral

11.

Hassan MQ,Gordon JA,Beloti MM,Croce CM,van Wijnen AJ,Stein JL,Stein GS,Lian JB. (2010). A network connecting Runx2, SATB2, and the miR-23a~27a~24-2 cluster regulates the osteoblast differentiation program. Proc Natl Acad Sci U S A, 107(46), 19879-19884. https://doi.org/10.1073/pnas.1007698107CrossRefPubMedPubMedCentral

12.

Dobreva G,Chahrour M,Dautzenberg M,Chirivella L,Kanzler B,Farinas I,Karsenty G,Grosschedl R. (2006). SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell, 125(5), 971-986. https://doi.org/10.1016/j.cell.2006.05.012CrossRefPubMed

13.

Magnusson K,de Wit M,Brennan DJ,Johnson LB,McGee SF,Lundberg E,Naicker K,Klinger R,Kampf C,Asplund A, et al. (2011). SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol, 35(7), 937-948. https://doi.org/10.1097/PAS.0b013e31821c3daeCrossRefPubMed

14.

Dragomir A,de Wit M,Johansson C,Uhlen M,Ponten F. (2014). The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study. Am J Clin Pathol, 141(5), 630-638. https://doi.org/10.1309/AJCPWW2URZ9JKQJUCrossRefPubMed

15.

Davis JL,Horvai AE. (2016). Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas. Histopathology, 69(1), 84-90. https://doi.org/10.1111/his.12911CrossRefPubMed

16.

Conner JR,Hornick JL. (2013). SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology, 63(1), 36-49. https://doi.org/10.1111/his.12138CrossRefPubMed

17.

De Michele S,Remotti HE,Del Portillo A,Lagana SM,Szabolcs M,Saqi A. (2021). SATB2 in Neoplasms of Lung, Pancreatobiliary, and Gastrointestinal Origins. Am J Clin Pathol, 155(1), 124-132. https://doi.org/10.1093/ajcp/aqaa118CrossRefPubMed

18.

Ma C,Olevian D,Miller C,Herbst C,Jayachandran P,Kozak MM,Chang DT,Pai RK. (2019). SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer. Mod Pathol, 32(8), 1217-1231. https://doi.org/10.1038/s41379-019-0265-1CrossRefPubMed

19.

Warmke LM,Maloney N,Leung CH,Lin H,Lazar AJ,Wang WL. (2022). SATB2 Expression in Undifferentiated Pleomorphic Sarcomas of Bone. Am J Clin Pathol, 158(2), 235-241. https://doi.org/10.1093/ajcp/aqac033CrossRefPubMed

20.

Machado I,Navarro S,Picci P,Llombart-Bosch A. (2016). The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas. Pathol Res Pract, 212(9), 811-816. https://doi.org/10.1016/j.prp.2016.06.012CrossRefPubMed

21.

Creytens D. (2020). SATB2 and TLE1 Expression in BCOR-CCNB3 (Ewing-like) Sarcoma, Mimicking Small Cell Osteosarcoma and Poorly Differentiated Synovial Sarcoma. Appl Immunohistochem Mol Morphol, 28(1), e10-e12. https://doi.org/10.1097/PAI.0000000000000601CrossRefPubMed

22.

Berg KB,Churg A. (2017). GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung. Am J Surg Pathol, 41(9), 1221-1225. https://doi.org/10.1097/PAS.0000000000000825CrossRefPubMed

23.

Ponten F,Jirstrom K,Uhlen M. (2008). The Human Protein Atlas--a tool for pathology. J Pathol, 216(4), 387-393. https://doi.org/10.1002/path.2440CrossRefPubMed

24.

Haase J,Misiak D,Bauer M,Pazaitis N,Braun J,Potschke R,Mensch A,Bell JL,Dralle H,Siebolts U, et al. (2021). IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis. Mod Pathol, 34(1), 32-41. https://doi.org/10.1038/s41379-020-0630-0CrossRefPubMed

25.

Koster J,Volckmann R,Zwijnenburg D,Molenaar P,Versteeg R. (2019). Abstract 2490: R2: Genomics analysis and visualization platform. Cancer Research, 79(13_Supplement), 2490–2490. https://doi.org/10.1158/1538-7445.Am2019-2490

26.

Luo H,Xia X,Kim GD,Liu Y,Xue Z,Zhang L,Shu Y,Yang T,Chen Y,Zhang S, et al. (2021). Characterizing dedifferentiation of thyroid cancer by integrated analysis. Sci Adv, 7(31). https://doi.org/10.1126/sciadv.abf3657

27.

Mao R,Shi L,Yan W,Li W,Li B,Li X. (2020). Anaplastic thyroid carcinoma combined with sclerosing mucoepidermoid carcinoma with eosinophilia: A case report. Medicine (Baltimore), 99(42), e22783. https://doi.org/10.1097/MD.0000000000022783CrossRefPubMed

28.

Nguyen D,Htun NN,Wang B,Lee B,Johnson C. (2023). An Anaplastic Thyroid Carcinoma of the Giant-Cell Type from a Mediastinal Ectopic Thyroid Gland. Diagnostics (Basel), 13(18), 2941. https://doi.org/10.3390/diagnostics13182941CrossRefPubMed

29.

Kamashki A,Rivera M,Sturgis C. (2023). Fine Needle Aspiration and Core Biopsy of Liver Mass as First Time Diagnosis of Sarcomatoid Anaplastic Thyroid Carcinoma, A Rare Malignancy Presenting at an Unexpected Body Site. American Journal of Clinical Pathology, 160(Supplement_1), S58-S58. https://doi.org/10.1093/ajcp/aqad150.130

30.

Dum D,Kromm D,Lennartz M,De Wispelaere N,Buscheck F,Luebke AM,Burandt E,Menz A,Kluth M,Hube-Magg C, et al. (2023). SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors. Arch Pathol Lab Med, 147(4), 451-464. https://doi.org/10.5858/arpa.2021-0317-OACrossRefPubMed

31.

Mneimneh WS,Asa SL. (2024). Divergent Lineage Markers in Anaplastic Thyroid Carcinoma. Am J Surg Pathol, 48(2), 230-237. https://doi.org/10.1097/PAS.0000000000002153CrossRefPubMed

32.

Hornick JL. (2014). Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors. Mod Pathol, 27 Suppl 1(1), S47–63. https://doi.org/10.1038/modpathol.2013.177

33.

Roy SK,Shrivastava A,Srivastav S,Shankar S,Srivastava RK. (2020). SATB2 is a novel biomarker and therapeutic target for cancer. J Cell Mol Med, 24(19), 11064-11069. https://doi.org/10.1111/jcmm.15755CrossRefPubMedPubMedCentral

34.

Yu W,Ma Y,Shankar S,Srivastava RK. (2016). Role of SATB2 in human pancreatic cancer: Implications in transformation and a promising biomarker. Oncotarget, 7(36), 57783–57797. https://doi.org/10.18632/oncotarget.10860

35.

Kucuksayan H,Ozes ON,Akca H. (2016). Downregulation of SATB2 is critical for induction of epithelial-to-mesenchymal transition and invasion of NSCLC cells. Lung Cancer, 98, 122-129. https://doi.org/10.1016/j.lungcan.2016.05.032CrossRefPubMed

36.

Yu W,Ma Y,Shankar S,Srivastava RK. (2017). SATB2/beta-catenin/TCF-LEF pathway induces cellular transformation by generating cancer stem cells in colorectal cancer. Sci Rep, 7(1), 10939. https://doi.org/10.1038/s41598-017-05458-yCrossRefPubMedPubMedCentral

37.

Zhang W,Wang J,Huang D,Liu Z,Lu T,Cui C,Li Z. (2024). Single-cell sequencing reveals SATB2/NOTCH1 signaling promotes the progression of malignancy of epithelial cells from papillary thyroid cancer. Mol Carcinog, 63(1), 22-33. https://doi.org/10.1002/mc.23631CrossRefPubMed

38.

Fujiwara-Tani R,Mori S,Ogata R,Sasaki R,Ikemoto A,Kishi S,Kondoh M,Kuniyasu H. (2023). Claudin-4: A New Molecular Target for Epithelial Cancer Therapy. Int J Mol Sci, 24(6). https://doi.org/10.3390/ijms24065494

39.

Tzelepi VN,Tsamandas AC,Vlotinou HD,Vagianos CE,Scopa CD. (2008). Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod Pathol, 21(1), 22-30. https://doi.org/10.1038/modpathol.3800959CrossRefPubMed

40.

Suren D,Yildirim M,Sayiner A,Alikanoglu AS,Atalay I,Gunduz UR,Kaya V,Gunduz S,Oruc MT,Sezer C. (2017). Expression of claudin 1, 4 and 7 in thyroid neoplasms. Oncol Lett, 13(5), 3722-3726. https://doi.org/10.3892/ol.2017.5916CrossRefPubMedPubMedCentral

41.

Fabbro D,Di Loreto C,Beltrami CA,Belfiore A,Di Lauro R,Damante G. (1994). Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res, 54(17), 4744–4749. https://www.ncbi.nlm.nih.gov/pubmed/8062273

42.

Nonaka D,Tang Y,Chiriboga L,Rivera M,Ghossein R. (2008). Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol, 21(2), 192-200. https://doi.org/10.1038/modpathol.3801002CrossRefPubMed

43.

Bishop JA,Sharma R,Westra WH. (2011). PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. Hum Pathol, 42(12), 1873-1877. https://doi.org/10.1016/j.humpath.2011.02.004CrossRefPubMed

44.

Lai WA,Hang JF,Liu CY,Bai Y,Liu Z,Gu H,Hong S,Pyo JY,Jung CK,Kakudo K, et al. (2020). PAX8 expression in anaplastic thyroid carcinoma is less than those reported in early studies: a multi-institutional study of 182 cases using the monoclonal antibody MRQ-50. Virchows Arch, 476(3), 431-437. https://doi.org/10.1007/s00428-019-02708-4CrossRefPubMed

45.

Lai WA,Liu CY,Lin SY,Chen CC,Hang JF. (2020). Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies RAS and PIK3CA Mutations as Negative Survival Predictors. Cancers (Basel), 12(7), 1973. https://doi.org/10.3390/cancers12071973CrossRefPubMed

46.

Wang JR,Montierth M,Xu L,Goswami M,Zhao X,Cote G,Wang W,Iyer P,Dadu R,Busaidy NL, et al. (2022). Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precis Oncol, 6(6), e2100504. https://doi.org/10.1200/PO.21.00504CrossRefPubMedPubMedCentral

47.

Volante M,Lam AK,Papotti M,Tallini G. (2021). Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know? Endocr Pathol, 32(1), 63-76. https://doi.org/10.1007/s12022-021-09665-2CrossRefPubMedPubMedCentral

48.

Yoo SK,Song YS,Lee EK,Hwang J,Kim HH,Jung G,Kim YA,Kim SJ,Cho SW,Won JK, et al. (2019). Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nat Commun, 10(1), 2764. https://doi.org/10.1038/s41467-019-10680-5CrossRefPubMedPubMedCentral

49.

Liao X,Oltvai ZN,Zhang D. (2023). Synchronous triple thyroid neoplasms with unique molecular alterations: A rare case report. Human Pathology Reports, 33, 300709. https://doi.org/10.1016/j.hpr.2023.300709CrossRef

Title: SATB2 is an Emergent Biomarker of Anaplastic Thyroid Carcinoma: A Series with Comprehensive Biomarker and Molecular Studies
Authors: Dingani Nkosi
William E. Crowe
Brian J. Altman
Zoltán N. Oltvai
Ellen J. Giampoli
Moises J. Velez
Publication date: 05-11-2024
Publisher: Springer US
Keywords: Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: Endocrine Pathology
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI: https://doi.org/10.1007/s12022-024-09833-0

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content

Keynote series | Spotlight on menopause

Keynote webinar | Spotlight on adolescent vaping

Keynote webinar | Spotlight on modern management of frailty

A quick guide to ECGs

At a glance: The STEP trials